Guidant Clarifies J&J Merger Terms, Incentives For Execs, Antitrust Defense
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug-eluting stent market will prove “sufficiently competitive” for FTC when U.S. pipeline is considered, Guidant CEO Dollens says in justifying the company’s expectation that no material divestitures will result from acquisition by J&J. Guidant exec affirms that preserving “iterative capability” of DES, delivery systems is central to merger plans.